Deep Track Capital Reports New 9.99% Passive Stake in Altimmune, Inc. via Warrants and Common Stock

On April 30, 2026, Deep Track Capital, LP filed a Schedule 13G reporting a new 9.99% passive stake in Altimmune, Inc. (ALT). The filing, triggered by an event on April 23, 2026, reveals that Deep Track Capital, LP and its affiliates, including Deep Track Biotechnology Master Fund, Ltd., Deep Track Special Opportunities Fund, LP, and David Kroin, collectively beneficially own 19,417,221 shares of common stock. The reported holdings include significant derivative positions consisting of 10,750,000 Pre-Funded Warrants and 30,000,000 standard Warrants. Notably, these warrants are subject to a beneficial ownership limitation (blocker) that prevents the reporting persons from exercising any portion that would result in owning more than 9.99% of the issuer's outstanding common stock. Specifically, Deep Track Biotechnology Master Fund, Ltd. holds an 8.65% interest (16,828,258 shares), while Deep Track Special Opportunities Fund, LP holds 1.33% (2,588,963 shares). David Kroin, as a control person, shares voting and dispositive power over the aggregate 9.99% position. The acquisition was made in the ordinary course of business without the intent to influence control of the issuer.